Lexicon Pharmaceuticals (LXRX) Gross Margin (2016 - 2026)

Lexicon Pharmaceuticals (LXRX) has 10 years of Gross Margin data on file, last reported at 99.49% in Q1 2026.

• On a quarterly basis, Gross Margin rose 187.0% year-over-year to 99.49% in Q1 2026; TTM through Mar 2026 was 99.49%, a 146.0% increase from a year earlier, with the FY2025 full-year figure at 99.45%, up 143.0% from the prior year.
• Gross Margin for Q1 2026 stood at 99.49%, up from 96.34% in the prior quarter.
• Over the last five years, Gross Margin for LXRX reached as high as 100.0% in Q2 2022 and fell as low as 89.92% in Q2 2024.
• Historically, Gross Margin has averaged 96.83% across 5 years, with a median of 97.25% in 2023.
• Across the five-year window, Gross Margin sank 733 bps in 2024 and jumped 996 bps in 2025, its largest moves.
• Year by year, Gross Margin stood at 100.0% in 2022, then dropped by 9 bps to 90.86% in 2023, then increased by 9 bps to 98.69% in 2024, then slipped by 2 bps to 96.34% in 2025, then gained by 3 bps to 99.49% in 2026.
• Per Business Quant data, the three most recent Gross Margin figures were 99.49% in Q1 2026, 96.34% in Q4 2025, and 99.93% in Q3 2025.